Get Nobivac ®

EDGE™ DAPPv

Canine EDGE™ DAPPv is a 0.5mL, combined vaccination approved for protection against canine distemper virus, adenovirus type 1 (hepatitis), canine parainfluenza virus, and canine parvovirus.

NOBIVAC EDGE™ DAPPV PROVIDES PROTECTION AGAINST FOUR KNOWN VIRUSES IN A 0.5 ML VACCINE

Canine Distemper Virus, Canine Adenovirus 1 (hepatitis), Canine Parainfluenza Virus, Canine Parvovirus (modified live viruses).

PRODUCT LABEL
  • Protects against all known strains of CPV, including CPV-2c2,3
  • High antigenic mass (titer), low passage parvovirus vaccine
  • Canine vaccine containing CPV-2b, one of the most prevalent field strains of parvovirus
  • Protects against adenovirus type 1 that causes hepatitis in dogs
  • Provides disease coverage for commonly spread canine viruses, distemper, adenovirus types 1, parainfluenza and parvovirus in 1 formula

INDICATIONS:

Effective for the vaccination against distemper, adenovirus type 1 (hepatitis), parainfluenza, and parvovirus in one formula.

Recommended for use in healthy dogs 6 weeks of age or older.

Efficacy & Comparisons

PROTECT AGAINST ALL KNOWN STRAINS OF CANINE PARVOVIRUS (CPV), INCLUDING CPV-2C

References 2,3,8

PROVEN IN AN INDEPENDENT STUDY BY LARSON AND SCHULTZ2

  • No clinical signs of disease were seen in Nobivac-vaccinated puppies after challenge with mixed CPV-2b and CPV-2c strains2
  • First published data showing protection against CPV-2c challenge2
  • All vaccinated puppies were protected from disease
  • All control puppies developed disease and 50% died or were euthanized

NOBIVAC EDGE™ DAPPV—A PROVEN FOUNDATION FOR VACCINE PROTOCOLS

D–CANINE DISTEMPER VIRUS (CDV)

  • Onderstepoort-type strain in Nobivac® vaccines provides a high level of safety1

A–CANINE ADENOVIRUS TYPE 2 (CAV-2)

  • Protection against CAV-1 (hepatitis) without the side effects associated with modified live CAV-1 vaccines4

P–CANINE PARAINFLUENZA VIRUS (CPIV)

  • Systemic administration stimulates a strong IgG response1

No items to show.

NOBIVAC EDGE™ DAPPV IS A SAFE CHOICE

  • Safety confirmed in 346-dog field study1
  • Proven safe across a variety of dog breeds and ages
  • Featuring an even higher level of quality due to VacciPure™ filtration

ADMINISTRATION AND DOSAGE

  • Subcutaneous injection
  • Primary vaccination may begin as early as 6 weeks
  • Repeat at 2 to 4 week intervals until the dog is 12 weeks of age
  • The need for annual revaccination has not been established
  • Available in a 25 x 0.5 mL dose presentation

ALSO AVAILABLE IN OTHER FORMULATIONS

DISEASE INFORMATION

Professional Resources and Educational Materials

Keep your clinic and staff informed and aware of diseases and outbreaks.

Quick Guide to Lepto

eBook

A handy guide to protect dogs and prevent the spread of leptospirosis.

Download

Nobivac® Social Media Kits

Digital Assets

Use these ready-to-share posts to educate pet parents and drive business to your clinic for preventative care.

Download

AAHA Canine Vaccination Guidelines

In-depth information about canine vaccinations and veterinary best practices.

Download

No items to show.

View More Nobivac® Resources

References:

1. Data on file, Merck Animal Health. 

2. Larson LJ, Schultz RD. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther. 2008;9(2):94–101. 

3. Schultz RD, Thiel B, Mukhtar E, Sharp P, Larson LJ. Age and long-term protective immunity in dogs and cats. J Comp Pathol. 2010;142 Suppl 1:S102–S108. 

4. Greene C, Rupprecht C. Rabies and other lyssavirus infections. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 3rd ed. St. Louis, MO: Saunders/Elsevier; 2006:167–183. 

8. Spibey N, Greenwood NM, Sutton D, Chalmers WS, Tarpey I. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol. 2008;128(1-2) :48-55.

View All Nobivac References